30 results about "Antiangiogenesis Therapy" patented technology

The present invention relates to a method for monitoring subjects being on anti-angiogenesis therapy based on determining the amount of a cardiac troponin in a first and second sample of a subject and comparing the amount in the first sample with the second sample. Thereby, it can be assessed whether a subject is susceptible to a continuation of the therapy or not. Moreover, the present invention relates to a method for predicting the risk of a cardiovascular event as a consequence of anti-angiogenesis therapy. Also encompassed by the present invention are kits and devices adapted to carry out the method of the present invention.

The invention provides methods of using expression levels of one or more stroma signature genes as selection criteria for determining a patient with cancer that is chemotherapy-resistant who may benefit from a particular anti-cancer therapy, such as stroma-targeted therapy, anti-angiogenic therapy, and/or immunotherapy. The present invention also provides methods of using expression levels of one or more stroma signature genes as a selection criterion for treating cancer patients, such as ovarian cancer patients, with a stroma-targeted agent.

Disclosed are copper-binding compounds with improved properties and methods of using such compounds in the prevention and treatment of angiogenic diseases, such as cancer. Advantages of the invention include the enhanced stability of the compounds, which is achieved without reduction in efficacy. Pharmaceutical compositions, therapeutic kits and combination treatment methods and uses are also provided.

Anti-angiogenic treatments, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of reducing the risk of pre-eclampsia and compounds for use in such methods are described.

The invention discloses a bio-click-triggered high-efficiency targeting conjugate and a bio-click-triggered high-efficiency targeting multi-component composition as well as preparation methods and application thereof. The multi-component composition is formed by assembling an anti-angiogenic therapeutic agent, a chemotherapeutic drug and a photosensitizer in the same nano-system; furthermore, thetargeting conjugate (a cycloalkyne-heparin polysaccharide-natural active hydrophobic medicine) is modified with a small molecular target with a cycloalkyne structure, so that in-vivo click targeting is efficiently realized. After nanoparticles are formed in water by means of self-assembly, a chemotherapeutic medicine and a thermotherapy photosensitizer are simultaneously encapsulated in hydrophobic cores of the nanoparticles by using a physical method; therefore, the toxic and side effects on the normal tissues are greatly reduced while the combined administration is realized; the conjugate and the multi-component composition have the characteristics of being intelligent, efficient and low in toxicity, having targeting property, reversing tumor MDR, having a synergistic anti-tumor effect,and the like; a brand-new combined chemotherapy model is created.

The use in the medical-surgical field of biomaterials based on hyaluronic acid derivatives, optionally in association with natural, synthetic or semisynthetic biopolymers, for suppressing the angiogenic process associated with tumour proliferation (in primary and secondary tumours) is disclosed.

A method for increasing the sensitivity of a tumor to anti-angiogenic therapy comprises treating a patient having a tumor with an anti-angiogenic therapeutic composition or compound and substantially simultaneously inhibiting vascular, or vasculogenic, mimicry (VM). In one embodiment, such a method includes the inhibition of VM by administering a therapeutic compound that inhibits the activity or pathway of the transcription factor FOXC2. In another embodiment, such a method includes administering a therapeutic compound that activates or enhances the activity or pathway of IRE1 and/or inhibits its target genes. In another embodiment, all three compositions are administered to the subject either simultaneously or sequentially.

The invention discloses the application of CD93 in the preparation of an early warning infantile hemangioma (IH) umbilical blood assay kit and a therapeutic drug. A study found that the neonatal umbilical blood serum CD93 has an important role in predicting/warning IH, and is a serum marker of IH tumors. Because IH is the most common benign tumor in infants, and the neonatal umbilical blood is easy to sufficiently collect in the early stage of IH, has no trauma, and is easy to be accepted by family members, the development of using CD93 as a umbilical blood assay kit or test paper for predicting/warning protein for warning the occurrence of IH has extremely important clinical significance and social values on the early monitoring, the early detection and the early treatment of IH, minimizing the teratogenesis rate of severe IH, and reducing the rate of misdiagnosis and mistreatment. In addition, the CD93, as transmembrane protein, can promote angiogenesis of hemangioblast stem cells, has important significance in anti-angiogenesis therapeutic targets, and can be used for preparing related therapeutic drugs and preventive drugs for early treatment and prevention of IH.

Anti-angiogenic treatments, for example treatment of ocular neovascularization or cancer, treatments of hyperpermeability disorders, treatments of neuropathic and neurodegenerative disorders, pain treatments, methods of treating or preventing fibrosis and compounds for use in such methods are described.

Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an anti-angiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.

The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the treatment of a patient suffering from cancer based on the genotype of KDR gene and/or EGF. The invention further relates to a method for reducing the risk of hypertension associated with an anti-angiogenesis therapy, such as bevacizumab, in a patient suffering from cancer by determining the genotype of KDR gene and/or EGF gene.